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OBJECTIVES: To determine owners’ perception of their pet’s quality of life during treatment with 
carboplatin for a variety of canine and feline neoplasms. METHODS: Owners were contacted via a 
postal questionnaire and asked questions regarding their perception of chemotherapy in pets and their 
perception of carboplatin treatment in their pet. RESULTS: Twenty-eight (59%) of owners responded 
to the questionnaire. Forty-three percent of owners had not considered chemotherapy in pets before 
treatment; however, after treatment, 89% of owners supported its use. Sixteen (57%) patients had mild 
to severe side effects. Most patients experienced mild side effects, including lethargy and loss of 
appetite. Quality of life during treatment was reduced compared with prediagnosis quality of life 
however at its best was significantly improved compared with pretreatment quality of life. Eighty-nine 
per cent of respondents did not regret treating their pet. CLINICAL SIGNIFICANCE: Carboplatin is 
well tolerated by both owners and pets. Most patients have either no side effects or experience mild 
lethargy or inappetence. Carboplatin treatment, either alone or in conjunction with other medications, 
should be considered as a palliative treatment in both dogs and cats with susceptible neoplasms.  
Carboplatin (cis-diammine-1,1-cyclobutane decarboxylate platinum (II) carboplatin) is a second 
generation platinum chemotherapy agent that is used in a variety of tumours in dogs and cats (Page and 
others 1993, Kisseberth and others 2008). Phase I clinical trials have been performed in both dogs and 
cats, and a maximum toxic dose and suggested dosing schedule have been established in both species 
(Page and others 1993, Kisseberth and others 2008). Reported dosing regimes are 300 mg/m2 
intravenously every 3 weeks in dogs, and 200 to 240 mg/m2 intravenously every 28 days in cats (Hahn 
and others 1997, Kisseberth and others 2008).  
 
The side effect profile has also been documented in both species. Carboplatin appears to be well 
tolerated with mild to moderate gastrointestinal and hematologic side effects (neutropenia and throm-
bocytopenia) being most common (Page and others 1993, Hahn and others 1997, Kisseberth and others 
2008).  
 
Myelosuppression is the dose-limiting toxicity in both dogs and cats (Page and others 1993, Kisseberth 
and others 2008). In dogs, the reported nadir for both neutrophils and platelets is around 14 days, with 
recovery by 21 days after treatment. In cats, the nadir of neutrophils is seen between 17 and 21 days, 
with recovery evident in most patients by day 28 after treatment (Fox 2000). Thrombocytopenia is seen 
infrequently in cats; however, the nadir is similar to the neutrophil nadir (Kisseberth and others 2008).  
For most veterinary patients, carboplatin is a palliative treatment. Reported uses for carboplatin include 
as a single agent or part of a multi-modality treatment protocol for various carcinomas (Murphy and 
others 2006, Dominquez and others 2009), as part of a treatment regime for canine nasal tumours 
(Langova and others 2004) and anal sac adenocarcinomas (Bennett and others 2002) and as an 
adjunctive treatment for canine appendicular osteosarcoma (Bergman and others 1996) and malignant 
melanoma (Freeman and others 2003). Intravenous carboplatin use in cats is less frequently reported; 
however, reported uses include extraskeletal osteosarcoma (Spugnini and others 2001, Dhaliwal and 
others 2003) and a variety of sarcomas and carcinomas (Kisseberth and others 2008). Carboplatin has 
also been reported to be administered by intracavitary injection for mesothelioma in dogs and cats 
(Spugnini and others 2008) and intralesional injection for feline squamous cell carcinoma (Theon and 
others 1996).  
 
Evaluation of veterinary patient quality of life is a relatively recent concept (Yeates and Main 2009). 
Many human oncology studies focus on evaluating patient quality of life as well as more traditional 
survival parameters (Osoba 1992). In contrast, veterinary studies have historically focussed on survival 
parameters, such as median survival time, time to tumour progression and quantitative assessment of 
tolerability and side effects. Although owners are interested in this information, many owners are very 
concerned about their pet’s quality of life during the treatment, especially, if the treatment is palliative 
(Mellanby and others 2003). One study involving cardiac patients showed that the patient’s quality of 
life was the most important factor in the decision to euthanase their pet (Freeman and others 2005). 
Also, veterinarians strive to improve quality of life in their patients (Yeates and Main 2009). Recent 
studies have evaluated owners’ perception of quality of life in patients receiving lymphoma 
chemotherapy (Mellanby and others 2003, Tzannes and others 2008) which showed that owners 
generally felt positive about lymphoma chemotherapy. A questionnaire study was also recently 
published evaluating owners’ perception of medical treatment of cancer showing that owners generally 
were positive regarding medical treatment of cancer (Bronden and others 2003). Owners’ perception of 
patient quality of life has not been established in patients receiving intravenous carboplatin 
chemotherapy. The aim of this study was to evaluate owners’ perception of quality of life in patients 
receiving carboplatin in combination with other medications for palliative treatment of a variety of neo-
plasms. The assessment of the patient’s quality of life was made by the owners in a retrospective 
manner, although the study did include some patients currently receiving carboplatin.  
 
MATERIALS AND METHODS  
This study was conducted in accordance with the Unitec Research Ethics Committee guidelines.  
 
The patient database from the medicine department at the Veterinary Specialist Group (VSG), 
Auckland, and the patient database at Catmed, Lower Hutt, were reviewed for the period of 2004 to 
2009 and all patients receiving one or more doses of intravenous carboplatin were identified. Both 
centres are private specialist referral practices in New Zealand. Management of cases from both centres 
was considered to be similar; dogs and cats were included in the study, if they had received one or 
more doses of carboplatin. Concurrent medications were allowed. Radiation therapy was not performed 
in either institution during the study period as radiation therapy is not available for pets in New 
Zealand. All patients were client owned animals and each owner gave informed consent to administer 
carboplatin before administration.  
 
Information regarding the patient’s species, breed, sex, age, presenting signs, diagnosis, the treatment 
protocol, number of cycles of treatment, treatment delays, concurrent medications and reported side 
effects were recorded from the case records.  
 
Owners were contacted via a postal questionnaire and were asked a series of questions (Appendix) to 
evaluate the patient’s quality of life before cancer, after diagnosis of cancer, but before treatment and 
during treatment with carboplatin. The owners were asked to rate their pet’s quality of life according to 
a 10-point numerical rating system with one being “quality of life could not be worse”, and 10 being 
“quality of life could not be better”. Scores were treated as continuous and were able to be marked 
anywhere along the scale (see Appendix). However, all scores marked on the scales by the participants 
were either whole numbers or exactly between two numbers. Owners were also asked to evaluate their 
perception of chemotherapy in pets both before and after treating their pet. Assessment of the patient’s 
side effects was rated as mild, moderate or severe. Criteria were not detailed for any severity level and 
owners could choose whichever category they felt appropriately classified the clinical signs. Final 
questions evaluated owners’ satisfaction with the treatment according to their pet’s quality of life and 
whether they regretted their decision to treat with carboplatin. Respondents were not questioned as to 
the average quality of life of their pet during the treatment protocol. Respondents answered 
anonymously. Owners were given an option not to complete the questionnaire and to withdraw from 
the study up to 2 weeks after completion of the study period. Non-respondents were not contacted 
again as non-return of the questionnaire was taken as unwillingness to participate in the study.  
Data analysis was performed using SPSS 17·0. Differences in quality of life scores were evaluated 
using a non-parametric Wilcoxon signed-rank test due to the small sample size and moderate skewness 
of the data. Since there were six independent hypothesis tests being examined, a Bonferroni correction 
was used to adjust the level of significance from the standard 0·05 to 0·008 (0·05 of 6).  
RESULTS 
Forty-seven patients met the study inclusion criteria. Twenty-eight (59%) owners completed the 
questionnaire. Twenty-seven patients were treated at VSG and one patient at Catmed clinic. Twenty-
three dogs and five cats were included in the study. The mean duration from initiation of carboplatin 
treatment to questionnaire was 22·7 months (range 1 to 51 months).  
 
Twenty-six patients (22 canine and 4 feline patients) received other medications during the time they 
were treated with carboplatin. Seventeen dogs (74%) and two cats (40%) received non-steroidal anti-
inflammatory medications (the type chosen at the clinician’s discretion). Seven dogs (30%) received 
doxorubicin. Other medications received by both dogs and cats included metoclopramide (seven), 
codeine or tramadol (five), bisphosphonate (four), potentiated amoxicillin (four) and mirtazapine 
(three).  
 
Twelve canine breeds were represented. Of the canine patients, 13 patients were neutered females, 9 
were neutered males and 1 an entire male. The median age of dogs at presentation was 11 years (range 
5 to 16 years). Seven tumour types were represented; osteosarcoma (seven cases), nasal carcinoma (six 
cases), oral malignant melanoma (three cases), thyroid carcinoma (two cases) and one each of tonsillar 
squamous cell carcinoma, anal gland adenocarcinoma and hepatocellular carcinoma. One patient had a 
solitary pulmonary mass which was not biopsied.  
 
The 23 patients had 99 carboplatin doses. The median number of doses was three per patient (range 1 
to 12 doses). The median dose was 300 mg/m2 (range 240 to 300 mg/m2). There were three dose 
reductions due to side effects (details were not specified in the records). Sixteen of 23 dogs had clinical 
signs related to their tumour before treatment with carboplatin. Nine of these patients had an 
improvement in their clinical signs.  
 
Of the five feline patients, three were domestic shorthair cats and two were Birmans. Two feline 
patients were neutered females and three were neutered males. The median age of cats at presentation 
was 12 years (range 5 to 18 years). Two feline patients had poorly differentiated metastatic carcinoma 
and the remaining three had one each of renal carcinoma, pancreatic carcinoma and thymoma. Five 
patients had 17 doses of carboplatin. The median number of doses was two per patient (range two to six 
doses). The median dose was 200 mg/m2 (range 180 to 210 mg/m2) with one dose reduction during 
treatment due to neutropenia and one dose reduction at initiation of treatment due to presenting 
azotemia. Three of the five feline patients had clinical signs related to their tumour before treatment 
with carboplatin and one patient experienced an improvement.  
 
Before their pet’s treatment, 12 (43%) owners had not thought about the use of chemotherapy in 
animals. Nine (32%) supported the use of chemotherapy, six (21%) were equivocal and only one (4%) 
owner disagreed with the use of chemotherapy in animals. After treatment, 24 (89%) owners supported 
the use of chemotherapy in animals, including the owner who initially disagreed with its use. No 
owners disagreed with the use of chemotherapy in animals after treating their pet; however, three 
owners were equivocal regarding the use of chemotherapy in companion animal medicine. One owner 
did not answer this question.  
When asked whether they would treat another pet with carboplatin in the unlikely event this was 
required, 19 (68%) owners answered in the affirmative. Eight (28%) owners were undecided and one 
owner said they would not treat another pet with carboplatin. This owner also regretted treating their 
pet with carboplatin. Sixteen (57%) owners said they would treat with a different form of 
chemotherapy in the unlikely event another pet required chemotherapy. Nine owners were undecided, 
citing it would depend on the diagnosis and prognosis, while three said they would not pursue other 
chemotherapy options in their pets. One of these owners regretted treating their pet with carboplatin, 
the other two did not.  
Sixteen (57%) patients experienced side effects during their carboplatin treatment protocols (13 dogs 
and 3 cats). Side effects were considered by the owner to be mild (six cases), mild to moderate (one 
case), moderate (two cases) and moderate to severe (three cases). Side effects included tiredness and 
lethargy (15), loss of appetite (7), vomiting (3), diarrhoea (2) and hematochezia (1). Tiredness/ lethargy 
was considered mild (10), moderate (3), mild to moderate (1) and severe (1). Loss of appetite was 
considered mild (three), moderate (one), mild to moderate (one) and severe (two). Vomiting was 
considered mild, moderate and severe with one case in each category. Diarrhoea was considered mild 
to moderate in one case and severe in one case. The patient with severe diarrhoea also had hematoche-
zia reported. Only one patient with mild side effects required treatment (for loss of appetite). Patients 
with moderate to severe side effects required treatment for a variety of side effects (including loss of 
appetite (four), lethargy (two), diarrhoea (two), vomiting (one) and hematochezia (one)).  
 
Table 1 shows the descriptive statistics for the quality of life scores at the various stages of illness. The 
mean and median quality of life scores are presented in the table, but the analysis focusses on the 
median differences due to the skewness of median quality of life score before the diagnosis was 10. 
Twenty-five owners reported that their pet’s quality of life decreased, resulting in a significantly lower 
quality of life score (P<0·001) once the diagnosis of cancer was made but before treatment was 
initiated (Table 2). The median decrease in the quality of life during treatment was also significant 
relative to precancer levels; at its best (median=8, P<0·001), and at its worst (median=5, P<0·001). At 
its best, the median difference in the quality of life scores was significant, indicating higher scores for 
most patients during treatment compared to before  treatment (but  postdiagnosis) (P=0·005). Eighteen 
patients had an increase in quality of life scores, five remained the same and only four patients 
experienced a decrease in their quality of life scores at its best during the treatment compared with 
pretreatment (but postdiagnosis) quality of life. At its worst, however, the median quality of life scores 
was not significantly different when compared to the pretreatment (but postdiagnosis) scores 
(P=0·044). At its best during treatment (median=8), the quality of life scores were significantly higher 
than at its worst (median=5) (P<0·001).  
 
Eighteen (64%) owners stated that the cost of treatment did not matter. Eight owners found the cost 
acceptable for the benefit. Two respondents chose option “other” and wrote individual comments rather 
than choosing a suggested comment. One owner felt the “cost was not acceptable for the time it gave”. 
This patient had severe side effects, no improvement in its clinical signs and the owners regretted the 
treatment. The remaining owner commented that the treatment was “too expensive but the extra time 
was great”.  
 
Twenty-three (82%) owners reported treating with carboplatin did not alter their relationship with their 
pet. One owner reported that their relationship deteriorated but was still acceptable. This patient had 
mild to moderate side effects and the owner would treat with carboplatin again if required however 
regretted treatment in this pet. Four owners reported that their relationship improved. Three of these 
patients had mild side effects.  
 
Owners were asked whether they regretted treating their pet with carboplatin. Twenty-five (89%) 
owners did not regret their decision to treat. Three owners regretted treatment.  
DISCUSSION  
This study showed that the majority of owners felt that their experience with carboplatin in conjunction 
with other palliative treatments was positive and that most owners would treat another pet with 
carboplatin if it were required. More than half the patients had side effects during their treatment 
protocol and only 58% of pets had an improvement in their initial presenting signs. Even so, treating 
with carboplatin changed most owners’ ideas about chemotherapy in pets from negative or neutral to 
positive. This positive experience parallels the results of other veterinary oncology quality of life 
studies (Mellanby and others 2003, Bronden and others 2003, Tzannes and other 2008). Interestingly, 
one respondent was adverse to chemotherapy in pets before proceeding with carboplatin treatment. The 
reason behind this is not clear due to the anonymity of the questionnaire, which was a requirement of 
the study’s ethics committee. However, it may be that the respondent filling in the questionnaire was 
not the owner who made the initial decision to proceed with  treatment and that their opinion 
subsequently changed with treatment, or it may be that their reasoning behind being adverse to 
treatment was based on misconceptions about the treatment (for example, side effects, quality of life 
concerns, costs of treatment in general or carboplatin in particular and so on) and once able to make an 
informed decision their perception of chemotherapy in pets changed.  
 
Although most owners felt that their experience with carboplatin treatment was positive, 11% (three 
owners) regretted treatment. Owners were not asked in the questionnaire their reasons for regretting 
treatment; however, these reasons could be multi-factorial and include a lack of response to treatment, 
unrealistic expectations, side effects of the medication(s), a decrease in quality of life for their pet 
during treatment or financial or emotional costs of palliative treatment. Also, some pets experienced 
owner rated poor quality of life during the time they received carboplatin. This could have been due to 
side effects of the treatments they received, or due to progression of an underlying disease process, or a 
combination of the two.  
 
Owners were more likely to retrospectively rate the carboplatin treatment as negative if their pet had no 
improvement in their clinical signs. They were also more likely to rate treatment as negative if their pet 
experienced side effects during treatment. It is possible that owners had difficulty separating the 
clinical signs associated with the underlying disease process from side effects associated with 
treatment, and therefore may have overestimated the number or severity of the side effects their pets 
experienced. Conversely, it is also possible that owners underestimated the severity of clinical signs in 
their pets. This may have been due to a variety of reasons including a desire to remember only positive 
experiences with their pet or recall bias due to the length of time between treatment and questionnaire.  
Even though patients had reduced quality of life scores during treatment compared with their precancer 
diagnosis quality of life, at its best, treatment did improve the quality of life significantly from 
pretreatment quality of life. At its worst, there was a non-significant trend towards worse quality of life 
compared with pretreatment quality of life scores. This is encouraging information for both clinicians 
and clients alike. Despite a decrease in quality of life compared to prediagnosis, only three owners 
regretted treatment. Tolerance to a decrease in quality of life has also previously been reported in 
owners whose cats were receiving chemotherapy for lymphoma (Tzannes and others 2008). This may 
reflect a more motivated population of owners who are more willing to tolerate a reduction in quality of 
life for a perceived or hoped increased quantity of life (Tzannes and others 2008).  
 
A great deal of variation was noted in patient quality of life during the time they received carboplatin. 
The median decrease in the quality of life scores from at their best during treatment (median=8) to at 
their worst (median=5) was significantly greater than zero (P<0·001). There was also a variation in 
quality of life between patients. At its best, quality of life scores varied from 3 to 10 whereas at its 
worst, quality of life scores varied from 1 to 9·5. This inter-individual variation could represent the 
variation in either the underlying disease process between patients or side effects of the treatment 
regimes, with some patients experiencing owner rated severe side effects while some experienced no 
side effects. It was also possible that there was poor inter-observer reliability, as each owner could have 
a different perception or understanding of quality of life, different interpretations of the question and 
use of the grading scale.  
 
Most owners did not consider the cost of treatment to be a factor in the decision making process, or 
they felt that the cost of treatment was worth the perceived benefit. It is possible that this reflects a 
referral population who are potentially more willing or able to spend money on their pets; however, in 
a recent study, 70·8% of responding United Kingdom veterinary practices prescribed cytotoxic drugs, 
with the majority of these being primary care facilities (Cave and others 2007). It may be that pets are 
being acknowledged more as a family member than purely as an animal and that this may influence 
owners’ willingness to invest in a treatment for their pets that is considered palliative (Shaw and 
Lagoni 2007).  
 
Almost all patients included in the study received concurrent medications. Ideally, for a study on 
quality of life for a certain medication, the medication of interest would be the sole medication the 
patient received during the study period. However, given the palliative nature of carboplatin 
chemotherapy, patients are frequently prescribed multiple medications. Therefore, although not ideal 
from a research perspective, the results of the study do mirror the situation in clinical practice and 
therefore are potentially more relevant to clinicians and owners as it aligns more closely with what they 
will be experiencing. Given the number of concurrent medications, it is possible that respondents were 
attributing patient side effects to carboplatin when they were actually a result of one (or more) of the 
other medications they were receiving; thus overestimating the side effects seen with carboplatin use. 
Conversely, it is possible that they attributed the side effects of carboplatin to one of the other 
medications; therefore, resulting in an underestimation of actual side effects. Thirty per cent of dogs 
received doxorubicin before, during or after their treatment with carboplatin, which may have resulted 
in erroneous attribution of side effects to carboplatin (overestimating side effects) or to doxorubicin 
(underestimating side effects). Limitations notwithstanding, the results are still valuable to clinicians 
and owners as this is the way carboplatin is often used in practice.  
 
All but one owner felt that their relationship with their pet was either improved or the same as before 
treatment with carboplatin. The owner’s relationship, or human-companion animal bond is often 
paramount to owners and the thought of an intervention adversely affecting this bond or relationship is 
worrying to them (Friedmann and Son 2009). One owner commented that their relationship had 
improved with their pet because “they appreciated her more” as they “admired her strength and positive 
nature”. Only one owner felt that their relationship with their pet had deteriorated; this pet had mild to 
moderate side effects. Even though many of the patients had side effects, some of which were 
categorised as severe by the owners, the majority of owners did not feel that this adversely affected 
their relationship with their pet.  
 
Fifty-nine per cent of questionnaires were returned and this may have resulted in a sampling bias. Only 
one questionnaire was returned from the Catmed clinic. As the philosophy of treatment and treatment 
regimes were very similar at both centres, the authors chose not to exclude the questionnaire results 
from the study. Demographic information related to owners was not asked in the questionnaire to allow 
respondents’ to remain anonymous; therefore, comparisons of owners to see if the respondents were 
representative of the entire sampling population was not possible. Owners who were positive about the 
experience may have been more likely to respond than owners who had a negative or adverse 
experience (Edwards and others 2007). However, there were a number of side effects reported and a 
number of owners who regretted treatment. This suggests that the respondent’s may well be repre-
sentative of the sample population and therefore results may be a valid indicator of owner’s perception 
of their pet’s quality of life during carboplatin treatment. Also, most pets had side effects; however, 
most owners did not regret their decision to treat.  
 
There are no standardised quality of life instruments in veterinary medicine for evaluation of 
chemotherapy protocols (Wojciechowska and Hewson 2005). Human quality of life instruments for 
proxy informants has been adapted in numerous veterinary papers (Freeman and others 2003, Mellanby 
and others 2003, Tzannes and others 2008). A number of studies have been performed assessing quality 
of life in pets using a Likert scale or numerical rating scale to assess the owner’s perception of quality 
of life. In human studies, proxy informants have been shown to both underestimate and overestimate 
quality of life (Yazbec and Fantoni 2005, Jozefiak and others 2008). This has not been studied in 
veterinary medicine as it is impossible to comment on quality of life from the animal’s point of view 
(as all assessments are still human rated parameters); however, this effect may exist (Yeates and Main 
2009) and therefore it may be that owners as proxy informants also underestimate or overestimate their 
pet’s quality of life.  
 
Specific criteria were not given to denote what were classified as mild, moderate or severe side effects. 
Medically, side effects can be very specifically graded (for example grade I diarrhoea is classified as 
soft formed faeces while grade II diarrhoea is classified as less than seven watery stools for less than 7 
days (Cave 2006)). One owner may feel that the presence of diarrhoea was enough to classify it as 
severe while another owner may classify medically severe diarrhoea as mild or moderate. Criteria such 
as this were not set as the question regarding the owners perception of their pet’s side effects was to 
obtain just that, their perception.  
 
Quantification of quality of life using a numerical rating scale is not standardised as each individual 
will have their own scale with which to judge the response (Yeates and Main 2009). A score of 10 in 
one pet may be the equivalent of a seven in another. The question regarding patient’s quality of life 
before the development of cancer was asked in an effort to account for individual differences with the 
numerical rating scale (Mellanby and others 2003). The numerical rating scale was chosen as it 
potentially provided a more sensitive index of patient’s quality of life than choosing between three or 
four categories (Mellanby and others 2003). A 1- to 10-point scale was chosen to minimise potential 
over-inflation of quality of life that may have occurred if the lowest point was zero. Owners may have 
been less willing to use numbers closer to or including zero if they felt they would be judged for 
consenting to a treatment which afforded no quality of life (at best) or possibly suggesting the patient 
died due to the side effects of the treatment regime.  
 
The questions included in this paper were subjective in nature. A previous paper assessing quality of 
life in pets with cancer pain suggested that subjective questions may not allow the true condition of an 
animal to be assessed (Yazbec and Fantoni 2005). Subjective questions were chosen as the owners 
were asked the questions in a retrospective manner and were potentially less likely to remember specif-
ics of their pet’s behaviour and demean-our. Some patients received carboplatin up to 5 years 
previously and therefore there may be a degree of recall bias in the results (Tzannes and others 2008). 
It is possible that some patients may have had side effects recorded in their records but not recalled by 
the owners in the questionnaire, however, as the owners answered the questionnaires anonymously, this 
information is not available.  
 
The results of this study may be complicated by recall bias. As the study was retrospective in nature, 
many respondents were answering questions about events which happened up to five years previously. 
A study in human medicine conducted over a four year period showed recall bias with some facts (such 
as the brand of medication) but not others (such as length of use of medication) (Nischan and others 
1993). It is also possible that any recall bias was further complicated by the proxy informant 
classification of the respondents.  
 
A specific limitation of this study is that a question was not asked regarding average quality of life 
during treatment. The absence of this data means that we cannot comment on whether owners 
perceived quality of life to be generally improved or worse than pretreatment (postdiagnosis) quality of 
life. This information would be interesting and beneficial to both owners and clinicians and further 
studies would be useful to evaluate this information. Also, further evaluation into the percentage time 
the owners felt they experienced good or bad quality of life would be beneficial.  
 
The response rate was lower in this study than a previously published veterinary oncology survey 
(Tzannes and others 2008), but is similar to previously published human medical surveys (Bergk and 
others 2005). Many factors have been reported to be associated with increased or decreased response 
and it may be that the reason for this is multi-factorial (Edwards and others 2007). The sample size was 
small reducing the ability to obtain subgroup comparisons. There were insufficient numbers to allow 
statistical assessment of owners’ feelings regarding treatment and regrets compared with the 
occurrence of clinical signs.  
 
Despite the limitations, this study found that carboplatin treatment was well tolerated by both owners 
and patients, many patients had an improvement in their cancer-related clinical signs and for at least 
some of the time during treatment patients had an improvement in their quality of life compared with 
that before treatment. Most owners had no regrets regarding treatment. These findings indicate that 
veterinarians should feel confident offering carboplatin alone or in conjunction with other medications 
(such as non-steroidal anti-inflammatories, doxorubicin, potentiated amoxicillin and metoclopramide) 
as a palliative treatment for susceptible neoplasia in dogs and cats.  
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